Two bioAffinity Technologies (BIAF) directors will not seek re-election in 2026

Rhea-AI Filing Summary

bioAffinity Technologies, Inc. reported that directors Robert Anderson and Roby Joyce have chosen not to stand for re-election when their current terms expire at the company’s 2026 Annual Meeting of Stockholders, currently scheduled for April 30, 2026.

The company stated that the decisions by Mr. Anderson and Mr. Joyce are not due to any disagreements with bioAffinity Technologies regarding its operations, policies, or practices. Both will continue to serve as directors until their terms end at the 2026 Annual Meeting.

false 0001712762 0001712762 2026-03-05 2026-03-05 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2026-03-05 2026-03-05 0001712762 BIAF:WarrantsToPurchaseCommonStockMember 2026-03-05 2026-03-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 5, 2026

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41463		46-5211056
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.007 per share		BIAF		The Nasdaq Stock Market LLC (Nasdaq Capital Market)
Warrants to purchase Common Stock		BIAFW		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 5, 2026, Robert Anderson and Roby Joyce informed the Board of Directors (the “Board”) of bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), of their decisions not to stand for re-election to the Board upon expiration of their current terms, which expire at the Company’s 2026 Annual Meeting of Stockholders, currently scheduled for April 30, 2026 (the “Annual Meeting”). Mr. Anderson’s and Mr. Joyce’s decisions not to stand for re-election at the Annual Meeting did not result from any disagreements with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 6, 2026	BIOAFFINITY TECHNOLOGIES, INC.
	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

FAQ

What board change did bioAffinity Technologies (BIAF) disclose in this 8-K?

bioAffinity Technologies disclosed that directors Robert Anderson and Roby Joyce will not stand for re-election at the 2026 Annual Meeting, scheduled for April 30, 2026. Both will remain on the board until their current terms expire at that meeting.

Did Robert Anderson or Roby Joyce resign immediately from the BIAF board?

No, Robert Anderson and Roby Joyce did not resign immediately. They informed bioAffinity Technologies that they will not stand for re-election when their terms end at the 2026 Annual Meeting, and will continue serving as directors until that meeting occurs.

Were there any disagreements behind the BIAF directors’ decision not to seek re-election?

The company stated that Robert Anderson’s and Roby Joyce’s decisions did not result from any disagreements with bioAffinity Technologies on matters related to its operations, policies, or practices. This suggests routine board turnover rather than a dispute-driven departure.

When is bioAffinity Technologies’ 2026 Annual Meeting of Stockholders scheduled?

bioAffinity Technologies’ 2026 Annual Meeting of Stockholders is currently scheduled for April 30, 2026. The terms of directors Robert Anderson and Roby Joyce expire at this meeting, and they have chosen not to stand for re-election at that time.

Who signed the 8-K filing for bioAffinity Technologies (BIAF)?

The 8-K was signed on behalf of bioAffinity Technologies by Maria Zannes, who is identified as the company’s President and Chief Executive Officer. Her signature confirms the company’s authorization and the accuracy of the disclosed board changes.

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.7 KB
• EX-101 XBRL DEFINITION FILE 26.0 KB
• EX-101 XBRL LABEL FILE 35.8 KB
• EX-101 XBRL PRESENTATION FILE 24.6 KB